Latest development in explainable AI and Clinical Drug Development : panel discussion at the Precision Medicine World Conference, June 15th 2021

The Precision Medicine WorlConference PMWC21 will showcase the growing role of Artificial Intelligence in significantly increasing the outlook of success in drug development while reducing clinical trials timelines. AI has been successfully guiding the determination of optimal dose, optimal drug combinations, patient selection biomarkers as well as potential additional indications. 

Precision Medicine World Conference, June 15th 2021: Ariana’s CEO, Mohammad Afshar, will be discussing the latest developments in explainable AI impacting the design of Precision Medicine clinical trials, along distinguished co-panelists Colin Hill, GNS Healthcare, Siddhartha Roychoudhury, Amgen, and Iya Khalil, Novartis.

The conference will showcase the growing role of Artificial Intelligence successfully guiding the determination of optimal dose, optimal drug combinations, patient selection biomarkers as well as potential additional indications.

“The future of drug development and clinical trials is in Artificial Intelligence. The future is today!” says Mohammad Afshar.

He will discuss real examples from Ariana’s growing successful pipeline that includes oncology, immuno-oncology, CNS and auto-immune disease.

More information https://www.pmwcintl.com/covid/

Registration
2021-05-27T14:20:19+00:00May 26th, 2021|